Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas OlenckiRoberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, Rashmi Kumar

Research output: Contribution to journalReview articlepeer-review

167 Scopus citations

Abstract

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)151-159
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2015

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this